Wanda Figueroa
Infectious Disease · Newark, NJNPI 1194811463
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 61.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $7,489 and has fallen 79.0% since, to $1,570 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $32.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$9K
- Janssen Products, LP$2K
- Gilead$2K
- Merck$551
- Johnson & Johnson$510
- EMD Serono, Inc.$253
- plus $311 from 10 others
What the payments were for
- Consulting fees$6,35045%
- Travel & lodging$1,53411%
- Food & beverage$5,99342%
- Education$2682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 216 | $8,674 |
| Janssen Products, LP | 8 | $2,333 |
| Gilead | 114 | $1,512 |
| Merck | 34 | $551 |
| Johnson & Johnson | 30 | $510 |
| EMD Serono, Inc. | 14 | $253 |
| Theratechnologies Inc. | 8 | $136 |
| Napo Pharmaceuticals Inc | 2 | $32 |
| AbbVie | 1 | $29 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Symtuza$1,980
How this compares
$14,145 in reported general payments places this provider in the 90th percentile of 334 infectious disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 183 | $740,059 |
| DovatoDolutegravir Sodium/Lamivudine | 101 | $309,919 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 56 | $276,574 |
| CabenuvaCabotegravir/Rilpivirine | 24 | $166,628 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 26 | $115,253 |
| TivicayDolutegravir Sodium | 34 | $97,284 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $28,726 |
| Darunavir | 15 | $23,497 |
| Isentress HdRaltegravir Potassium | 11 | $22,083 |
| ValacyclovirValacyclovir Hcl | 39 | $1,202 |
| Ritonavir | 14 | $828 |
| Rosuvastatin Calcium | 40 | $633 |
| Atorvastatin Calcium | 24 | $132 |
| Labetalol Hcl | 14 | $110 |
| Enalapril Maleate | 20 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,512 | $884,038222 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Tivicay | $8,674 | $573,831159 claims |
| Janssen Products, LPSymtuza | $2,333 | $276,57456 claims |
| MerckIsentress Hd | $551 | $22,08311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Newark
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Shobha SwaminathanNewark$60K
- Sally HodderNewark$47K
- Madhu SuryadevaraNewark$24K
- Alexander StolerNewark$6K
- Hamid ShaabanNewark$5K
- Keith GottesdienerRahway$2.1M
- Ronald NahassHillsborough$213K
- Christopher LucastiSomers Point$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.